Top View
- Safety Data for Lirilumab in Combination with Nivolumab Or Ipilimumab Announced at ESMO 2016 Congress
- Overview of Development Pipeline Progress Status in Second Quarter of Fiscal Year 2017
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- A61K9/51 (2006.01) — with International Search Report (Art
- Phase II Combination of Lirilumab and Nivolumab with 5-Azacitidine in Patients with Myelodysplastic Syndromes (MDS) 2014-0934
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- Strategy, Efficacy and Safety of Combination Regimens Using Immunotherapy Rebecca C
- Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
- Compilation of Abstract Titles from ASCO Annual Meeting 2021 (Oral, Poster Discussion, Posters, Mains Track by Cancer Types Only)
- Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4 Shuang Qin1, Linping Xu2, Ming Yi1, Shengnan Yu1, Kongming Wu1,2* and Suxia Luo2*
- 1078-0432.CCR-19-2214.Full.Pdf
- (12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
- An Open-Label Phase II Study of Lirilumab (BMS
- Immuno-Oncology Combinations: a Review of Clinical Experience and Future Prospects
- Immunotherapy – a Novel Facet of Modern Therapeutics Immunotherapy – a Novel Facet of Modern Therapeutics Sujata P
- Clinical Trials
- Harnessing the Innate Immune System and Local Immunological Microenvironment to Treat Colorectal Cancer
- Structural Studies of a New Class of Immune Checkpoint
- Supplementary Tables and Figures Section 1. Distribution of CDR-H3
- Immuno-Oncology
- Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
- Immuno-Oncology Combinations: a Review of Clinical Experience And
- Tryptophan Catabolism As Immune Mechanism of Primary Resistance to Anti-PD-1
- ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
- Novel Insights Into the Immunotherapy of Soft Tissue Sarcomas: Do We Need a Change of Perspective?
- COMPASS Report
- Was PD-L1 Test to Blame for Failure of Bristol's
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- (INN) for Biological and Biotechnological Substances
- Modulation of NK Cells with Checkpoint Inhibitors in the Context of Cancer Immunotherapy
- WO 2018/231759 Al 20 December 2018 (20.12.2018) W !P O PCT
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- Figure 2. Study Design for CA223-001
- WO 2018/200533 Al 01 November 2018 (01.11.2018) W !P O PCT
- A Phase 1B Study of Dual PD-1 and CTLA-4 Or KIR Blockade in Patients with Relapsed/Refractory Lymphoid Malignancies
- Paradigm Change in First-Line Treatment of Recurrent And/Or Metastatic Head and Neck Squamous Cell Carcinoma
- Lirilumab (Anti-KIR Mab) Combined with Rituximab for Relapsed, Refractory Or High-Risk Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
- Bristol-Myers Squibb Company PRI, Form 10-K for the Fiscal Year
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
- Immunotherapy for the Treatment of Head and Neck Cancers
- 5-1130 Leidner
- Current Antibody-Based Therapies for the Treatment of Multiple Myeloma